FDA Grants Priority Review Status to Sucampo Pharmaceuticals, Inc.'s AMITIZA® (lubiprostone) Submission Seeking Approval for Treatment of Opioid-induced Constipation

BETHESDA, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of their supplemental new drug application (sNDA) filing. The sNDA was filed in late July seeking approval for an additional indication for AMITIZA® (lubiprostone) for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.